{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T21:04:51Z","timestamp":1757624691172,"version":"3.44.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T00:00:00Z","timestamp":1667174400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020097","name":"Foundation for Opioid Response Efforts","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020097","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001872","name":"Vitalyst Health Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001872","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajpmfocus.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["AJPM Focus"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.focus.2022.100047","type":"journal-article","created":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T23:21:19Z","timestamp":1667604079000},"page":"100047","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Opportunities and Challenges: Hepatitis C Testing and Treatment Access Experiences Among People in Methadone and Buprenorphine Treatment During COVID-19, Arizona, 2021"],"prefix":"10.1016","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1762-7179","authenticated-orcid":false,"given":"Beth E.","family":"Meyerson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle M.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Missy","family":"Downer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amirah","family":"Alfar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Garnett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Lowther","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Lutz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8180-4040","authenticated-orcid":false,"given":"Arlene","family":"Mahoney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Greg","family":"Nu\u00f1ez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Savannah","family":"Samorano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3534-1027","authenticated-orcid":false,"given":"Benjamin R.","family":"Brady","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith G.","family":"Bentele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brenda","family":"Granillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.focus.2022.100047_bib0001","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.30297","article-title":"Estimating prevalence of Hepatitis C virus infection in the United States, 2013\u20132016","volume":"69","author":"MGo","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.focus.2022.100047_bib0002","unstructured":"Mapping hepatitis elimination in action. United States Health and Human Services (HHS). https:\/\/www.hhs.gov\/hepatitis\/mapping-hepatitis-elimination-in-action\/index.html Updated January 2022. Accessed July 2, 2022."},{"issue":"3","key":"10.1016\/j.focus.2022.100047_bib0003","doi-asserted-by":"crossref","first-page":"226","DOI":"10.7326\/M15-0320","article-title":"Limited access to new Hepatitis C virus treatment under state Medicaid programs","volume":"163","author":"Canary","year":"2015","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.focus.2022.100047_bib0004","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/PHH.0000000000000829","article-title":"Strategies for improving Hepatitis C treatment access in the United States: state officials address high drug prices, stigma, and building treatment capacity","volume":"25","author":"Kapadia","year":"2019","journal-title":"J Public Health Manag Pract"},{"issue":"3","key":"10.1016\/j.focus.2022.100047_bib0005","doi-asserted-by":"crossref","first-page":"215","DOI":"10.7326\/M15-0406","article-title":"Restrictions for Medicaid reimbursement of sofosbuvir for the treatment of Hepatitis C Virus infection in the United States","volume":"163","author":"Barua","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.focus.2022.100047_bib0006","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jsat.2019.01.021","article-title":"Barriers and facilitators of hepatitis C treatment uptake among people who inject drugs enrolled in opioid treatment programs in Baltimore","volume":"100","author":"Falade-Nwulia","year":"2019","journal-title":"J Subst Abuse Treat"},{"issue":"12","key":"10.1016\/j.focus.2022.100047_bib0007","first-page":"720","article-title":"Hepatitis C Virus detection and treatment in rural communities","volume":"14","author":"Gordon","year":"2018","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"10.1016\/j.focus.2022.100047_bib0008","unstructured":"Hepatitis C: State of Medicaid access: Arizona. National Viral Hepatitis Roundtable, 2021 (NVHR). https:\/\/stateofhepc.org\/states\/arizona\/. Updated October 2022. Accessed November 21, 2022."},{"issue":"2","key":"10.1016\/j.focus.2022.100047_bib0009","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/liv.13519","article-title":"In an era of highly effective treatment, hepatitis C screening of the United States general population should be considered","volume":"38","author":"Younossi","year":"2018","journal-title":"Liver Int"},{"issue":"9","key":"10.1016\/j.focus.2022.100047_bib0010","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1093\/cid\/cis011","article-title":"Cost-effectiveness and population outcomes of general population screening for hepatitis C","volume":"54","author":"Coffin","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.focus.2022.100047_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2021.103112","article-title":"I don't even want to go to the doctor when I get sick now: healthcare experiences and discrimination reported by people who use drugs, Arizona 2019","volume":"93","author":"Meyerson","year":"2021","journal-title":"Int J Drug Policy"},{"issue":"suppl 5","key":"10.1016\/j.focus.2022.100047_bib0012","doi-asserted-by":"crossref","first-page":"S365","DOI":"10.1093\/infdis\/jiaa207","article-title":"Hepatitis C among high-risk Alabamians: disease burden and screening effectiveness","volume":"222","author":"Lee","year":"2020","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.focus.2022.100047_bib0013","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1097\/PHH.0000000000001011","article-title":"Utilizing electronic laboratory reporting data to assess the burden of Hepatitis C in Arizona","volume":"26","author":"Tsang","year":"2020","journal-title":"J Public Health Manag Pract"},{"issue":"2","key":"10.1016\/j.focus.2022.100047_bib0014","first-page":"74","article-title":"Community reach: outcomes of a community-based screening program for hepatitis C among people who use drugs in Arizona","volume":"1","author":"Snyder","year":"2022","journal-title":"Sci J Health Sci Res"},{"issue":"S2","key":"10.1016\/j.focus.2022.100047_bib0015","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.2105\/AJPH.2021.306665","article-title":"The methadone manifesto: treatment experiences and policy recommendations from methadone patient activists","volume":"112","author":"Simon","year":"2022","journal-title":"Am J Public Health"},{"year":"2020","series-title":"The Opioid Fix: America's Addiction Crisis and the Solution They Don't Want You to Have","author":"Andraka-Christou","key":"10.1016\/j.focus.2022.100047_bib0016"},{"issue":"10","key":"10.1016\/j.focus.2022.100047_bib0017","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0274094","article-title":"Nothing really changed: Arizona patient experience of methadone and buprenorphine access during COVID","volume":"17","author":"Meyerson","year":"2022","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.focus.2022.100047_bib0018","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/add.12392","article-title":"'Not just methadone Tracy':transformations in service-user identity following the introduction of hepatitis C treatment into Australian opiate substitution settings","volume":"109","author":"Rance","year":"2014","journal-title":"Addiction"},{"issue":"6","key":"10.1016\/j.focus.2022.100047_bib0019","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/j.1360-0443.2008.02188.x","article-title":"Critical issues in the treatment of hepatitis C virus infection in methadone maintenance patients","volume":"103","author":"Novick","year":"2008","journal-title":"Addiction"},{"key":"10.1016\/j.focus.2022.100047_bib0020","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.drugalcdep.2019.01.037","article-title":"Strategies used by people who inject drugs to avoid stigma in healthcare settings","volume":"198","author":"Biancarelli","year":"2019","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"10.1016\/j.focus.2022.100047_bib0021","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1080\/09540260701278937","article-title":"Discrimination in healthcare against people with mental illness","volume":"19","author":"Thornicroft","year":"2007","journal-title":"Int Rev Psychiatry"},{"issue":"2","key":"10.1016\/j.focus.2022.100047_bib0022","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6902a1","article-title":"CDC recommendations for hepatitis C screening among adults \u2014 United States, 2020","volume":"69","author":"Schillie","year":"2020","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.focus.2022.100047_bib0023","unstructured":"FAQs: Provision of methadone and buprenorphine for the treatment of opioid use disorder in the COVID-19 emergency. Substance Abuse and Mental Health Services Administration (SAMHSA). https:\/\/tinyurl.com\/sxbcnh3. Updated April 21, 2020. Accessed May 1, 2020."},{"issue":"2","key":"10.1016\/j.focus.2022.100047_bib0024","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2105\/AJPH.2015.302927","article-title":"Cascade of care for hepatitis C virus infection within the U.S. Veterans Health Administration","volume":"106","author":"Maier","year":"2016","journal-title":"Am J Public Health"},{"issue":"4","key":"10.1016\/j.focus.2022.100047_bib0025","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/jpids\/piz065","article-title":"Hepatitis C virus screening among adolescents attending a drug rehabilitation center","volume":"9","author":"Fernandes","year":"2019","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"8","key":"10.1016\/j.focus.2022.100047_bib0026","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1111\/add.14978","article-title":"Cost-effectiveness of the HepCATT intervention in specialist drug clinics to improve case-finding and engagement with HCV treatment for people who inject drugs in England","volume":"115","author":"Ward","year":"2020","journal-title":"Addiction"},{"key":"10.1016\/j.focus.2022.100047_bib0027","unstructured":"Sharing the dream: Is the ADA accommodating all? Chapter 4: Substance Abuse under the ADA. U.S. Commission on Civil Rights. https:\/\/www.usccr.gov\/pubs\/ada\/ch4.htm. Accessed June 16, 2020."},{"key":"10.1016\/j.focus.2022.100047_bib0028","unstructured":"AHCCS Medicaid policy manual, section 320 \u2013 services with special circumstances. Arizona Health Care Cost Containment System. https:\/\/www.azahcccs.gov\/shared\/MedicalPolicyManual\/ Accessed November 21, 2022."},{"issue":"1\u20132","key":"10.1016\/j.focus.2022.100047_bib0029","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.drugalcdep.2013.02.018","article-title":"Stigma among health professionals towards patients with substance use disorders and its consequences for healthcare delivery: systematic review","volume":"131","author":"van Boekel","year":"2013","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.focus.2022.100047_bib0030","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.drugalcdep.2016.11.026","article-title":"Excess mortality among people who report lifetime use of illegal drugs in the United States: a 20-year follow-up of a nationally representative survey","volume":"171","author":"Walker","year":"2017","journal-title":"Drug Alcohol Depend"}],"container-title":["AJPM Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2773065422000451?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2773065422000451?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T14:50:21Z","timestamp":1757429421000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2773065422000451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S2773065422000451"],"URL":"https:\/\/doi.org\/10.1016\/j.focus.2022.100047","relation":{},"ISSN":["2773-0654"],"issn-type":[{"type":"print","value":"2773-0654"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Opportunities and Challenges: Hepatitis C Testing and Treatment Access Experiences Among People in Methadone and Buprenorphine Treatment During COVID-19, Arizona, 2021","name":"articletitle","label":"Article Title"},{"value":"AJPM Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.focus.2022.100047","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Inc. on behalf of The American Journal of Preventive Medicine Board of Governors.","name":"copyright","label":"Copyright"}],"article-number":"100047"}}